BAVC regimen in CR AML patients.
Meloni
G
G
Department of Human Biopathology, University La Sapienza, Roma, Italy.
Vignetti
M
M
De Fabritiis
P
P
Petti
M C
MC
Pinto
M R
MR
Testi
A M
AM
Vegna
M L
ML
Mandelli
F
F
D000293:Adolescent; D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality; D002330:Carmustine / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007223:Infant; D007558:Italy / Q000453:epidemiology; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000601:surgery*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012074:Remission Induction; D015996:Survival Rate; D014182:Transplantation, Autologous
D000677:Amsacrine; D003561:Cytarabine; D005047:Etoposide; D002330:Carmustine